Circulating HER2 Extracellular Domain and Response to Chemotherapy in Metastatic Breast Cancer

摘要: Purpose: The present study was designed to demonstrate the association between HER2 and chemotherapy resistance in patients with metastatic breast cancer. Patients methods: We performed a prospective assessment of predictive value circulating extracellular domain (ECD) carcinoma using paclitaxel doxorubicin. Serum samples were collected from 45 before first-line for disease levels ECD measured an enzyme immunoassay. Immunohistochemistry anti-HER2 monoclonal antibody CB11 used assess expression primary tumors. Results: When 450 fmol/ml as cutoff, 18 (40%) had elevated levels. Elevated associated tumor tissue burden (evaluated marker CA 15-3; p = 0.032 0.002, respectively) but not variables such menopausal status, stage at diagnosis, previous adjuvant therapy, or number sites. correlated inversely response treatment. probability obtaining complete significantly lower (p 0.021) (0%; 95% confidence interval, 0-13%) comparison non-elevated (26.9%; 12-45%). In addition, duration clinical shorter ECD, cases (7.5 versus 11 months; 0.035).